With the emergence of genomic profiling technologies and selective molecular targeted
therapies, biomarkers play an increasingly important role in the clinical management of …

Precision medicine is about matching the right drugs to the right patients. Although this
approach is technology agnostic, in cancer there is a tendency to make precision medicine …

Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …

The identification of specific genetic alterations as key oncogenic drivers and the
development of targeted therapies are together transforming clinical oncology and creating …

Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …

Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon
skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase …

Treatment for non-small-cell lung cancer is evolving from the use of cytotoxic chemotherapy
to personalised treatment based on molecular alterations. This past decade has witnessed …

Introduction Molecular genetic analyses of lung adenocarcinoma have recently become
standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed …

Purpose We report the experience with 2,000 consecutive patients with advanced cancer
who underwent testing on a genomic testing protocol, including the frequency of actionable …

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …